论文部分内容阅读
化学名 (-)-〔N-〔(S)-1-乙氧甲酰-3-苯丙基〕-L-丙酰基〕-L-脯氨酸马来酸盐药效分类血管紧张素Ⅰ转化酶抑制剂开发单位 (日)万有制药株式会社上市厂商 (日)万有制药株式会社1986年3月药理本药是在疏甲丙脯酸的结构上以苯丙胺取代其SH基而成。口服后水解成活性产物,可抑制血管紧张素转化酶,从而抑制肾素-血管紧张素系统从而呈降压作用。药动学本药口服后,血中原形药物浓度的达峰时间为1～2小时,其主要活性代谢
Chemical Name (-) - [N - [(S) -1-Ethoxycarbonyl-3-phenylpropyl] -L-propionyl] -L-Proline Maleate Pharmacodynamic Category Angiotensin I Invertase Enzyme Development Unit (Japan) Wannibalian Pharmaceutical Co., Ltd. Listed Company (Japan) Wannit Pharmaceutic Co., Ltd. Mar. 1986 Pharmacological This drug is based on the structure of the captopril substituted with phenylamine for its SH group. Oral hydrolysis into the active product, can inhibit angiotensin converting enzyme, thereby inhibiting the renin-angiotensin system and thus antihypertensive effect. Pharmacokinetics After oral administration of the drug, the blood concentration of prototype drug peak time of 1 to 2 hours, the main active metabolites